Added to YB: 2024-01-31
Pitch date: 2024-01-30
ARDX [bullish]
Ardelyx, Inc.
-30.22%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Market Cap
$1.4B
Pitch Price
$8.90
Price Target
15.00 (+142%)
Dividend
N/A
EV/EBITDA
-43.88
P/E
-24.60
EV/Sales
3.53
Sector
Biotechnology
Category
growth
Show full summary:
Ardelyx's XPHOZAH Still An Afterthought To The Pros
ARDX +230% on FDA nod for XPHOZAH (tenapanor) in hyperphosphatemia. Q3 rev $56M beat est, $22M IBSRELA sales, 75% gross margin. '23 sales target $80M, '24 $140-150M. XPHOZAH in 7/20 top plans, IBSRELA in 5/10. $184M cash. Risks: COGS, distribution. Eyeing pediatric use.
Read full article (9 min)